Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
Portfolio Pulse from
Alterity Therapeutics released its Q2 FY25 cash flow report, highlighting progress in its ATH434 clinical trials for neurodegenerative diseases. The company has a cash balance of A$4.54 million as of December 31, 2024, and expects to release topline data for its ATH434-201 trial by February 2025.
January 24, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alterity Therapeutics reported a productive Q2 FY25 with significant progress in its ATH434 trials, maintaining a cash balance of A$4.54 million. The company anticipates releasing topline data for its ATH434-201 trial by February 2025.
The report highlights positive developments in Alterity's ATH434 trials, which could lead to potential breakthroughs in treating neurodegenerative diseases. The cash balance indicates financial stability, and the upcoming data release could positively impact the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100